X0202 SCHEDULE 13G 0001674546 XXXXXXXX LIVE Common Stock 03/31/2026 0001590750 Viridian Therapeutics, Inc. 92790C104 221 Crescent Street Suite 103A Waltham MA 02453 Rule 13d-1(b) Bellevue Group AG a V8 0.00 6726144.00 0.00 6726144.00 6726144.00 N 6.6 HC CO The percentage set forth in Row 11 is calculated based on 102,458,094 shares of Common Stock deemed outstanding. Bellevue Asset Management AG a V8 0.00 6726144.00 0.00 6726144.00 6726144.00 N 6.6 CO The percentage set forth in Row 11 is calculated based on 102,458,094 shares of Common Stock deemed outstanding. Viridian Therapeutics, Inc. 221 Crescent Street, Suite 103A, Waltham, MA 02453 Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG"). Bellevue: Theaterstrasse 12, Zurich, Switzerland, CH-8001 BAM AG: Theaterstrasse 12, Zurich, Switzerland, CH-8001 Bellevue: Switzerland BAM AG: Switzerland N FI Swiss Financial Market Supervisory Authority (FINMA) 6,726,144 6.6% 0 6,726,144 0 6,726,144 Y Y N This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Bellevue Group AG /s/ Stefano Montalbano 05/15/2026 /s/ Christoph Eisenring 05/15/2026 Bellevue Asset Management AG /s/ Christoph Eisenring 05/15/2026 /s/ Ivo Betschart 05/15/2026